Assertio Holdings, Inc. Q3 2025 Earnings Recap

ASRT Q3 2025 November 12, 2025

Get alerts when ASRT reports next quarter

Assertio Holdings reported strong third-quarter results driven by the significant pull-forward in Rolvedon sales, culminating in a net product sales increase of over 150% year-over-year.

Earnings Per Share Beat

$1.65 vs $-1.20 est.

+237.5% surprise

Revenue Beat

49459000 vs 6199000 est.

+697.9% surprise

Market Reaction

1-Day -4.63%

5-Day -13.34%

30-Day -14.65%

See ASRT alongside your other holdings

Add to your portfolio — free

Key Takeaways

Rolvedon net product sales reached $38.6 million, up from $15 million in Q3 2024, bolstered by a strategic pull-forward in sales.
Adjusted EBITDA improved to $20.9 million, compared to $4.4 million in the same period last year.
Sympazan sales grew to $2.8 million, reflecting an increase in volume and underscoring the strength of the product's franchise in the market.
Assertio narrowed its 2025 guidance, accounting for the impact of the Rolvedon transition and competitive headwinds from Indocin and Otrexup.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit ASRT on AllInvestView.